OTC · Healthcare
CASI Pharmaceuticals, Inc. (CASIF)
As-reported financials and recent SEC filings for CASI Pharmaceuticals, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$20.7M
Net income
$-48.1M
Net margin
—
Diluted EPS
$-2.59
ROE
128.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $20.7M | $28.5M | $33.9M | $43.1M | $30.2M |
| Gross profit | $10.1M | $11.1M | $20.1M | $27.3M | $17.6M |
| Operating income | $-45.0M | $-39.6M | $-25.1M | $-34.0M | $-41.5M |
| Net income | $-48.1M | $-39.3M | $-27.0M | $-41.0M | $-36.7M |
| Diluted EPS | $-2.59 | $-2.56 | $-2.02 | $-3.01 | $-2.69 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
6-K2026-06-29
View on EDGAR →25-NSE2026-06-23
View on EDGAR →6-K2026-06-02
View on EDGAR →SCHEDULE 13D/A2026-05-18
View on EDGAR →20-F2026-05-15
View on EDGAR →D2026-04-28
View on EDGAR →32026-04-23
View on EDGAR →NT 20-F2026-04-21
View on EDGAR →Largest Healthcare peers
Go deeper on CASIF
Search CASI Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.